Cognitive and psychomotor effects of adjunctive aripiprazole or paliperidone in patients of schizophrenia receiving olanzapine: a double blind placebo controlled clinical study


  • Mayur M. Mayabhate Department of Pharmacology, Indira Gandhi Government Medical College and Hospital, Nagpur-440018, Maharashtra, India
  • Vandana A. Badar Department of Pharmacology, Indira Gandhi Government Medical College and Hospital, Nagpur-440018, Maharashtra, India
  • Praveer Waradkar Department of Psychiatry, Indira Gandhi Government Medical College and Hospital, Nagpur-440018, Maharashtra, India
  • Abhishek Somani Department of Psychiatry, Indira Gandhi Government Medical College and Hospital, Nagpur-440018, Maharashtra, India


Schizophrenia, Cognition, Psychomotor function, Aripiprazole, Paliperidone


Background: Emergence of atypical antipsychotics has revolutionized the treatment of schizophrenia by exploiting dual actions on serotonin as well as dopaminergic receptors. Still, monotherapy with these agents is insufficient to control cognitive and psychomotor as well as positive and negative symptoms. Hence combination therapy with antipsychotics is common in clinical practice. Objective of current study is to compare the effects of addition of aripiprazole or paliperidone on cognition and psychomotor functions in schizophrenia receiving olanzapine.

Methods: This is prospective, double blind, placebo controlled, parallel group study in 90 patients of schizophrenia showing partial or no response to olanzapine measured by Positive And Negative Symptoms Score (PANSS) scale. They were randomly divided to receive adjuvant aripiprazole, paliperidone or placebo for 6 weeks.

Results: Combination of aripiprazole and olanzapine shows significant improvement in most of the cognition and psychomotor parameters like attention, perception, verbal memory, thinking and processing as well as motor speed while combination of paliperidone and olanzapine is associated with improvement in only some of the cognitive and psychomotor parameters such as attention, perception and verbal memory only. Both the combinations are efficacious in controlling positive and negative symptoms of schizophrenia as assessed by PANSS scale.

Conclusions: The best augmenting strategy with for olanzapine nonresponsive patients will be D2 receptor partial agonist like aripiprazole rather than D2 antagonist like paliperidone and other atypical antipsychotic agents for better improvement in cognition and psychomotor domains.


Reus VI. Mental disorders. Harrison’s principles of internal medicine, 17th ed. Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, et al., editors. New York: Mc Graw Hill; 2008: 2710-2723.

Stahl SM. Essential psychopharmacology neuroscientific basis and practical application. 2nd ed. Cambridge: University Press; 2004: 365-458.

Lesh TA, Niendam TA, Minzenberg MJ and Carter CS. Cognitive control deficits in schizophrenia: Mechanisms and meaning. Neuropsychopharmacology. 201136(1):316–38.

Weickert TW, Goldberg TE. First and second generation antipsychotic medication and cognitive processing in schizophrenia. Curr Psychiatry Rep. 2005;7(4):304-10.

Morrens M, Hulstijn W, Sabbe B. Psychomotor slowing in schizophrenia. Schizophr Bull. 2007;33:1038-53.

Baldessarini RJ, Tarazi I. Pharmacotherapy of psychosis and mania. In: Goodman and Gilman’s the pharmacological basis of therapeutics. Brunton LL, Lazo JS, Pasrker KL, editors. New York: McGraw Hill; 2005: 461-500.

Zink M. Augmentation of olanzapine in treatment-resistant schizophrenia. J Psychiatry Neurosci. 2005;30(6):409-15.

Lerner V, Libov I, Kotler M, Strous RD. Combination of "atypical" antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(1):89-98.

Kane JM, Correll CU, Goff DC, Marder SR, Wei Sun, Kirkpatrick B, et al. A multicentre randomised double blind placebo controlled 16 week study of adjunctive aripiprazole for schizophrenia and schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry. 2009;70(10):1348-57.

Herbert Meltzer. (2009) Antipsychotic agents and lithium. In: Basic and clinical pharmacology. 11th edi. Katzung BG, Masters SB, Trevor AJ editors; 2009: 487-508.

Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T. et al. Aripiprazole, a novel antipsychotic, is a high affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302:381–9.

Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol. 2002;441:137–40.

Potkin SG, Saha AR, Kujawa MJ, Carson WH, Mirza A, Stock E. et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003;60:681–90.

Robert S. Kern, Michael F. Green, Barbara A. Cornblatt, J. Randall Owen, Robert D. McQuade, William H. Carson et al. The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology. 2006;187:312–20.

M. Riedel, R. Schennach-Wolff, R. Musil, S. Dehning, A. Cerovecki, M. Opgen-Rhein, J. et al. Neurocognition and its influencing factors in the treatment of schizophrenia—effects of aripiprazole, olanzapine, quetiapine and risperidone. Hum. Psychopharmacol Clin Exp. 2010;25:116–25.

The neurocognitive effects of aripiprazole compared with risperidone in the treatment of schizophrenia. Hiroshima J Med Sci (Japan). 2012;61(4):75-83.

Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ. et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003;61:123–6.

Belgamwar RB, El-Sayeh HG: Aripiprazole versus placebo for schizophrenia. Cochrane Database Syst Rev (England). 2011.

Chwieduk CM, Keating GM. Paliperidone extended release: a review of its use in the management of schizophrenia. Drugs. 2010;70(10):1295-317.

Houthoofd SA, Morrens M, Sabbe BG. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder. Clin Ther. 2008;30(9):1565-89.

Harvey PD, Napolitano JA, Mao L, Gharabawi G. Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. Int J Geriatr Psychiatry. 2003;18(9):820-9.

Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry (United States). 2007;64(6):633-47.

Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64(15):1715-36.

Mucci Armida, Piegari Giuseppe and Galderisi Silvana. Cognitive enhancing effects of aripiprazole : a case report. Clin Pract Epidemiol Ment Health. 2008;4:24.

Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry. 2008;165(11):1432-41.

Fowler JA, Bettinger TL, Argo TR. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia. Clin Ther. 2008;30(2):231-48.

Yang LP. Oral paliperidone: a review of its use in the management of schizoaffective disorder. CNS Drugs. 2011;25(6):523-38.

Stone BM. Pencil and paper tests- sensitivity to psychotropic drugs. Br J Clin Pharmacol. 1984;18:15S-20S.

Turner P. Critical flicker fusion frequency and centrally acting drugs. Br J Ophth. 1968;52:245-50.

Spreen O, Benton AL. Neurosensory center comprehensive examination for aphasia (NCCEA) (revised edition). University of Victoria, Neuropsychology Laboratory, Victoria, British Columbia. 1997.

McClelland GR, Cooper SM, Pilgrim AJ. A comparison of the central nervous system effects of haloperidol, chlorpromazine and sulpiride in normal volunteers. Br J Clin Pharmacol. 1990;30:795-803.

Kaur G, Sandhu SS, Sandhu SS. Comparison of arm-hand steadiness for shooting perfection in armed forces and Punjab police. Anthropologist 2007;9(4):299-304.

Sjøgren P, Christrup LL, Petersen MA, Højsted J. Neuropsychological assessment of chronic non-malignant pain patients treated in a multidisciplinary pain centre. Eur J Pain. 2005;9(4):453-62.

George P. Prigatano, Beate Hoffmann. Finger Tapping and Brain Dysfunction: A Qualitative and Quantitative Study. Borrow Quarterly. 1997;13(4).

Li Z, Ichikawa J, Dai J, Meltzer HY. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol. 2004;493(1-3):75-83.

Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(7):1159-72.

Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem. 2001;76(5):1521-31.

Goldberg TE, Goldman RS, Burdick KE, Malhotra AK, Lencz T, Patel RC et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry. 2007;64(10):1115-22.

Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the right stuff? Schizophr Bull. 2000;26:119–36.

D. Hughes and M. Morcos. Use of aripiprazole in treatment resistant schizophrenia. J Psychopharmacology. 2008;22:927.

Marder SR, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry. 2007;62(12):1363-70.

Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res. 2007;90(1-3):147-61.

Turkoz I, Bossie CA, Dirks B, Canuso CM. Direct and indirect effects of paliperidone extended release tablets on negative symptoms of schizophrenia. Neuropsychiatric Disease and Treatment. 2008;4(5):949-58.

Chavda RK, Laxmi L, Nair BS, Gandewar K. Efficacy and Tolerability of Aripiprazole in Patients with Schizophrenia & Schizoaffective Disorders. Indian Journal of Psychiatry. 2004;46(2):150-5.

Croxtall JD: Aripiprazole: a review of its use in the management of schizophrenia in adults. CNS Drugs (New Zealand). 2012;26(2):155-83.

Heydebrand G, Weiser M, Rabinowitz J, Hoff AL, De Lisi LE, Csernansky JG. Correlates of cognitive deficits in first episode schizophrenia. Schizophr Res. 2004;68:1–9.




How to Cite

Mayabhate, M. M., Badar, V. A., Waradkar, P., & Somani, A. (2017). Cognitive and psychomotor effects of adjunctive aripiprazole or paliperidone in patients of schizophrenia receiving olanzapine: a double blind placebo controlled clinical study. International Journal of Basic & Clinical Pharmacology, 3(1), 130–138. Retrieved from



Original Research Articles